Inaktiver Wert

Andere Sprachen Arsanis Inc Nasdaq

Aktien

US0428731097

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01.05.
X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024	30.04.
Pantherx® Rare Partner with X4 Pharmaceuticals Inc. for the Distribution of Xolremdi? (Mavorixafor), the First FDApproved Therapy Indicated for Use in Patients with Whim Syndrome	29.04.
X4 Pharmaceuticals' Xolremdi Approved by FDA For WHIM Syndrome	29.04.
X4 Pharmaceuticals Gets FDA Approval for Xolremdi Capsules	29.04.
X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome	29.04.
X4 Pharmaceuticals, Inc. Announces FDA Approval of XOLREMDI (mavorixafor) Capsules, First Drug Indicated in Patients with Whim Syndrome	29.04.
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	03.04.
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	02.04.
X4 Pharmaceuticals : Regulation FD Disclosure - Form 8-K	01.04.
X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences	01.04.
X4 Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21.03.
X4 Pharmaceuticals: Q4 Earnings Snapshot	21.03.
North American Morning Briefing : Investors -2-	21.03.
X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update	21.03.
X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host a Conference Call and Webcast on March 21, 2024	12.03.
Thinking about buying stock in Marpai, Axcelis Technologies, Amylyx Pharmaceuticals, Biomx, or X4 Pharmaceuticals?	11.03.
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	04.03.
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01.03.
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Arsanis Inc Nasdaq

Aktien

US0428731097

Andere Sprachen

Filter